Photo from wikipedia
Along with the development of novel migraine therapies as the monoclonal antibodies against calcitonin gene‐related peptide (CGRP) and its receptor, the question arises if the treatment of chronic migraine (CM)… Click to show full abstract
Along with the development of novel migraine therapies as the monoclonal antibodies against calcitonin gene‐related peptide (CGRP) and its receptor, the question arises if the treatment of chronic migraine (CM) and medication overuse headache (MOH) must be reconsidered. Have previous therapeutic approaches, including glucocorticoids, lost their role in the management of this debilitating disorder? In this narrative review, we present an overview of the available treatment options in CM and MOH in light of CGRP antibodies as well as an evaluation of the role of glucocorticoids in withdrawal therapy.
Journal Title: Headache
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!